Tamoxifen (Synonyms: ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen)

Name: Tamoxifen
Brand: MedChemExpress
SKU: HY-13757A
Rating: 5.0 (143 reviews)

Cat. No.: HY-13757A Purity: 99.78%: FAQs
Data Sheet
SDS

COA
Handling Instructions Technical Support

Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 μM and 1.8 μM, respectively. Tamoxifen activates autophagy and induces apoptosis. Tamoxifen also can induce gene knockout of CreER transgenic mouse.

For research use only. We do not sell to patients.

Tamoxifen Chemical Structure

CAS No. : 10540-29-1

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	In-stock	Estimated Time of Arrival: December 31
10 g	Get quote
50 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 143 publication(s) in Google Scholar

Other Forms of Tamoxifen:

Tamoxifen Citrate In-stock
Tamoxifen-d₅ Get quote
Tamoxifen-d₃ Get quote
Tamoxifen (Standard) Get quote

139 Publications Citing Use of MCE Tamoxifen

: Tamoxifen purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Dec;26(12):2099-2114. [Abstract]; Tamoxifen (2 mg/day; i.p.; for 5 consecutive days) can effectively induce the removal of NAT1 in various tissues, including muscle, white adipose tissue, pancreas, and liver, in adult Nat1^fl/fl;UBC^creERT2/+ mice and in Nat1^fl/fl;UBC^creERT2/+;Ripk1^D138N/D138N mice carrying a RIPK1 allele with an inactivation mutation.

: Tamoxifen purchased from MedChemExpress. Usage Cited in: Redox Biol. 18 October 2022, 102509.; Expression of TFRC in primary fibroblasts from TFRCflox/flox and TFRC−/− mice was assessed by western blot after 5 days of Tamoxifen intraperitoneal injection and 7 days of waiting.

: Tamoxifen purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2020 Jan;10(1):137-150. [Abstract]; Different transmission of MAPK8/FoxO signaling pathway in breast cancer cells (MCF-7, T47D, ZR-75, and MDA-MB-231) and liver cells (LO2) exposed to TAM (Tamoxifen).

: Tamoxifen purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2019 May 23;17(1):50. [Abstract]; Tamoxifen inhibits the growth and metastasis of prostate tumors in vivo. Western blot analysis of the indicated proteins in prostate primary tumors tissues.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Estrogen Receptor/ERR Isoform Specific Products:

View All Isoforms

Estrogen receptor ERα ERβ ERRα ERRβ ERRγ

View All HSP Isoform Specific Products:

View All Isoforms

HSP40 HSP70 HSP90 HSP105 HSF1 HSP HSPA5

Biological Activity
Purity & Documentation
References
Customer Review

Description

Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells^[1]^[2]^[3]. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 μM and 1.8 μM, respectively^[5]. Tamoxifen activates autophagy and induces apoptosis^[4]. Tamoxifen also can induce gene knockout of CreER transgenic mouse^[6].

IC₅₀ & Target^[1]^[4]

Estrogen receptor

HSP90

Cellular Effect

Cell Line	Type	Value	Description	References
518A2	IC₅₀	7.62 μM Compound: 2	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 22749392]
A2058	EC₅₀	12.5 μM Compound: TAM	Antiproliferative activity against human A2058 cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay Antiproliferative activity against human A2058 cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay	[PMID: 31099568]
A253 cell line	IC₅₀	8.92 μM Compound: 2	Cytotoxicity against human A253 cells after 96 hrs by SRB assay Cytotoxicity against human A253 cells after 96 hrs by SRB assay	[PMID: 22749392]
A2780	GI₅₀	30.3 μM Compound: 1	Cytotoxicity against human A2780 cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against human A2780 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 27128175]
A2780	IC₅₀	7.77 μM Compound: 2	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 22749392]
A-431	IC₅₀	> 100 μM Compound: Tamoxifen	Cytotoxicity against human A431 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human A431 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
A549	IC₅₀	1.86 μg/mL Compound: Tomoxifen	Cytotoxicity against human A549 cells by alamar blue assay Cytotoxicity against human A549 cells by alamar blue assay	[PMID: 11720540]
A549	IC₅₀	10.08 μM Compound: Tamoxifen	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
A549	IC₅₀	10.87 μM Compound: Tamoxifen	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 31546197]
A549	IC₅₀	12 μM Compound: TAM	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 23287057]
A549	IC₅₀	17.3 μM Compound: Tamoxifen	Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
A549	IC₅₀	17.3 μM Compound: Tamoxifen	Anticancer activity against human A549 cells measured after 48 hrs by SRB assay Anticancer activity against human A549 cells measured after 48 hrs by SRB assay	[PMID: 27671497]
A549	GI₅₀	24.4 μM Compound: Tamoxifen	Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
A549	IC₅₀	8.4 μM Compound: Tamoxifen	Cytotoxicity against human A549 cells assessed as cell viability by MTT assay Cytotoxicity against human A549 cells assessed as cell viability by MTT assay	[PMID: 26079090]
A549	IC₅₀	9.66 μM Compound: 2	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 22749392]
Astrocyte	IC₅₀	> 10 μM Compound: Tamoxifen	Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method	[PMID: 26355532]
B16-F10	IC₅₀	64.87 μM Compound: Tam	Antiproliferative activity mouse B16F10 cells after 2 days by MTT assay Antiproliferative activity mouse B16F10 cells after 2 days by MTT assay	[PMID: 25222876]
CHO	IC₅₀	> 100 μM Compound: Tam	Antiproliferative activity against CHO cells after 2 days by MTT assay Antiproliferative activity against CHO cells after 2 days by MTT assay	[PMID: 25222876]
DLD-1	IC₅₀	11.06 μM Compound: Tamoxifen	Anticancer activity against human DLD1 cells measured after 48 hrs by SRB assay Anticancer activity against human DLD1 cells measured after 48 hrs by SRB assay	[PMID: 27671497]
DLD-1	IC₅₀	16.3 μM Compound: Tamoxifen	Cytotoxicity against human DLD1 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human DLD1 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
DLD-1	IC₅₀	4.78 μM Compound: 2	Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay	[PMID: 22749392]
DU-145	IC₅₀	10.87 μM Compound: Tamoxifen	Antiproliferative activity against human DU145 cells by MTT assay Antiproliferative activity against human DU145 cells by MTT assay	[PMID: 31546197]
DU-145	IC₅₀	18.07 μM Compound: Tamoxifen	Anticancer activity against human DU145 cells measured after 48 hrs by SRB assay Anticancer activity against human DU145 cells measured after 48 hrs by SRB assay	[PMID: 27671497]
DU-145	GI₅₀	19.3 μM Compound: Tamoxifen	Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
DU-145	IC₅₀	28.9 μM Compound: Tamoxifen	Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
DU-145	IC₅₀	5.5 μM Compound: TAM	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 23287057]
DU-145	GI₅₀	6.07 μM Compound: Tamoxifen	Anticancer activity against human DU145 cells after 24 hrs by SRB assay Anticancer activity against human DU145 cells after 24 hrs by SRB assay	[PMID: 19733085]
EKVX	GI₅₀	6.3 μM Compound: TAM	Cytotoxicity against human EKVX cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human EKVX cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
FaDu	IC₅₀	5.39 μM Compound: Tamoxifen	Anticancer activity against human FADU cells measured after 48 hrs by SRB assay Anticancer activity against human FADU cells measured after 48 hrs by SRB assay	[PMID: 27671497]
Fibroblast	IC₅₀	> 20 μM Compound: TAM	Antiproliferative activity against mouse fibroblasts after 48 hrs by MTT assay Antiproliferative activity against mouse fibroblasts after 48 hrs by MTT assay	[PMID: 23287057]
Fibroblast	CC₅₀	11.1 μM Compound: Tamoxifen	Cytotoxicity against human HSF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HSF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33373820]
Fibroblast	CC₅₀	12.7 μM Compound: Tamoxifen	Cytotoxicity against human HSF cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay Cytotoxicity against human HSF cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay	[PMID: 33373820]
HCT-116	IC₅₀	45 μM Compound: Tamoxifen	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
HCT-15	GI₅₀	3.16 μM Compound: TAM	Cytotoxicity against human HCT15 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
HEK293	IC₅₀	> 50 μM Compound: Tamoxifen	Cytotoxicity against HEK293 cells by MTT assay Cytotoxicity against HEK293 cells by MTT assay	[PMID: 31546197]
HEK293	IC₅₀	10 μM Compound: Tamoxifen	Cytotoxicity against HEK293 cells after 24 hrs by MTT assay Cytotoxicity against HEK293 cells after 24 hrs by MTT assay	[PMID: 20605470]
HEK293	IC₅₀	10 μM Compound: Tamoxifen	Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay	[PMID: 21871812]
HEK293	CC₅₀	13 μg/mL Compound: TAM	Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis	[PMID: 30316060]
HEK293	CC₅₀	13.1 μg/mL Compound: Tamoxifen	Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 20 hrs by resazurin dye-based fluorescence assay Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 20 hrs by resazurin dye-based fluorescence assay	[PMID: 30901686]
HEK293	CC₅₀	13.1 μg/mL Compound: Tamoxifen	Cytotoxicity against human HEK293 cells assessed as reduction in cell growth incubated for 20 hrs by resazurin dye-based fluorometric assay Cytotoxicity against human HEK293 cells assessed as reduction in cell growth incubated for 20 hrs by resazurin dye-based fluorometric assay	[PMID: 30831407]
HEK293	IC₅₀	20.93 μM Compound: Tamoxifen	Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay	[PMID: 29054359]
HEK293	IC₅₀	22.4 μM Compound: TAM	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34153643]
HEK293	IC₅₀	24 μM Compound: Tamoxifen	Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 20 hrs by resazurin dye based assay Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 20 hrs by resazurin dye based assay	[PMID: 35477062]
HEK293	IC₅₀	24 μM Compound: Tamoxifen	Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay	[PMID: 30975502]
HEK293	IC₅₀	26 μM Compound: TAM	Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay	[PMID: 24457094]
HEK293	IC₅₀	26.33 μM Compound: 1	Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 35276362]
HEK293	CC₅₀	39.4 μM Compound: Tamoxifen	Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis	[PMID: 30322754]
HEK293	IC₅₀	50 μM Compound: Tamoxifen	Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay	[PMID: 24880230]
HEK293	CC₅₀	62 μM Compound: Tamoxifen	Cytotoxicity against HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay	[PMID: 28257200]
HEK293	CC₅₀	9 μg/mL Compound: Tamoxifen	Cytotoxicity against HEK293 cells assessed as cell viability after 20 hrs by fluorescence assay Cytotoxicity against HEK293 cells assessed as cell viability after 20 hrs by fluorescence assay	[PMID: 33609657]
HEK293	CC₅₀	9 μg/mL Compound: Tamoxifen	Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay	[PMID: 32619924]
HEK293	CC₅₀	9 μg/mL Compound: Tamoxifen	Cytotoxicity against human HEK-293 cells incubated for 23 hrs by CO-ADD method Cytotoxicity against human HEK-293 cells incubated for 23 hrs by CO-ADD method	[PMID: 33738069]
HEK-293T	IC₅₀	0.039 μM Compound: Tamoxifen	Antagonist activity at Gal4 DBD-fused human ERalpha LBD expressed in HEK293T cells assessed as inhibition of estradiol-induced transcriptional activation after 20 hrs by luciferase reporter gene assay Antagonist activity at Gal4 DBD-fused human ERalpha LBD expressed in HEK293T cells assessed as inhibition of estradiol-induced transcriptional activation after 20 hrs by luciferase reporter gene assay	[PMID: 23786452]
HeLa	IC₅₀	0.341 μM Compound: Tamoxifen	Antagonist activity at full length ERalpha (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay Antagonist activity at full length ERalpha (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay	[PMID: 28882502]
HeLa	IC₅₀	0.73 μM Compound: Tamoxifen	Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay	[PMID: 29624387]
HeLa	IC₅₀	1.53 μM Compound: Tamoxifen	Antagonist activity at full length ERbeta (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay Antagonist activity at full length ERbeta (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay	[PMID: 28882502]
HeLa	IC₅₀	10.87 μM Compound: Tamoxifen	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 31546197]
HeLa	GI₅₀	12 μM Compound: 1	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by trypan blue assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by trypan blue assay	[PMID: 27128175]
HeLa	IC₅₀	12.5 μM Compound: Tamoxifen	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 20605470]
HeLa	GI₅₀	32.6 μM Compound: 1	Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue assay Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue assay	[PMID: 23735829]
HeLa	IC₅₀	8.85 μM Compound: Tamoxifen	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 28838694]
Hepatocyte	EC₅₀	34.4 μM Compound: Tamoxifen	Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay	[PMID: 22531045]
Hepatocyte	EC₅₀	67.6 μM Compound: Tamoxifen	Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by LDH release assay Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by LDH release assay	[PMID: 22531045]
Hepatocyte	EC₅₀	71.4 μM Compound: Tamoxifen	Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay	[PMID: 22531045]
HepG2	IC₅₀	12 μM Compound: Tamoxifen	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 30613327]
HepG2	IC₅₀	19.6 μM Compound: Tamoxifen	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by cell-titer 96 aqueous one solution cell proliferation assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by cell-titer 96 aqueous one solution cell proliferation assay	[PMID: 34015704]
HepG2	GI₅₀	21.7 μM Compound: Tamoxifen	Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
HepG2	IC₅₀	23.4 μM Compound: tamoxifen	Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter-BlueCell viability assay Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter-BlueCell viability assay	[PMID: 20545334]
HepG2	CC₅₀	24.7 μM Compound: Tamoxifen	Cytotoxicity against human HepG2 cells after 24 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against human HepG2 cells after 24 hrs by resazurin dye-based fluorescence analysis	[PMID: 30322754]
HepG2	EC₅₀	35 μM Compound: Tamoxifen	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 4 hrs by CellTiter-Glo assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 4 hrs by CellTiter-Glo assay	[PMID: 27652492]
HepG2	EC₅₀	35 μM Compound: Tamoxifen	Cytotoxicity in human HepG2 cells assessed as induction of cell necrosis incubated for 4 hrs by LDH release assay Cytotoxicity in human HepG2 cells assessed as induction of cell necrosis incubated for 4 hrs by LDH release assay	[PMID: 27652492]
HepG2	IC₅₀	6.3 μM Compound: TAM	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23287057]
HepG2	CC₅₀	62 μM Compound: Tamoxifen	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay	[PMID: 28257200]
HL-60	IC₅₀	14.3 μM Compound: Tamoxifen	Cytotoxicity against human HL60 cells after 72 hrs by WST1 assay in presence of 20% FBS Cytotoxicity against human HL60 cells after 72 hrs by WST1 assay in presence of 20% FBS	[PMID: 22901895]
HL-60	IC₅₀	5.9 μg/mL Compound: 1, Tamoxifen	Growth inhibition of human HL60 cells after 4 hrs by MTT assay Growth inhibition of human HL60 cells after 4 hrs by MTT assay	[PMID: 17904372]
HT-29	IC₅₀	1.86 μg/mL Compound: Tomoxifen	Cytotoxicity against human HT-29 cells by alamar blue assay Cytotoxicity against human HT-29 cells by alamar blue assay	[PMID: 11720540]
HT-29	IC₅₀	38.6 μM Compound: tamoxifen	Cytotoxicity against human HT-29 cells after 24 hrs by CellTiter-BlueCell viability assay Cytotoxicity against human HT-29 cells after 24 hrs by CellTiter-BlueCell viability assay	[PMID: 20545334]
Ishikawa	IC₅₀	0.42 μM Compound: tamoxifen	Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 4 days by ELISA Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 4 days by ELISA	[PMID: 9784163]
Ishikawa	IC₅₀	14.58 μM Compound: Tamoxifen	Antiproliferative activity against ER-positive human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against ER-positive human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 34509864]
Ishikawa	IC₅₀	16.47 μM Compound: Tamoxifen	Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay	[PMID: 28460819]
Ishikawa	IC₅₀	16.78 μM Compound: Tamoxifen	Antiproliferative activity against human Ishikawa cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human Ishikawa cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay	[PMID: 34022716]
Ishikawa	IC₅₀	170 nM Compound: 1a	Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 72 hrs Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 72 hrs	[PMID: 18835176]
Ishikawa	IC₅₀	20.65 μM Compound: Tamoxifen	Cytotoxicity in human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity in human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 28942113]
Ishikawa	IC₅₀	22.5 μM Compound: Tamoxifen	Antiproliferative activity against human Ishikawa cells expressing estrogen receptor after 48 hrs by MTT assay Antiproliferative activity against human Ishikawa cells expressing estrogen receptor after 48 hrs by MTT assay	[PMID: 21871812]
Ishikawa	IC₅₀	26.52 μM Compound: Tamoxifen	Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay	[PMID: 29587221]
Ishikawa	IC₅₀	6 μM Compound: Tamoxifen	Antiproliferative activity against human Ishikawa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human Ishikawa cells incubated for 48 hrs by MTT assay	[PMID: 27176944]
Ishikawa	IC₅₀	7.87 μg/mL Compound: Tamoxifen	Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay	[PMID: 28442256]
J774.A1	CC₅₀	11.06 μM Compound: Tamoxifen	Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability incubated for 24 hrs by neutral red uptake assay Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability incubated for 24 hrs by neutral red uptake assay	[PMID: 31376569]
Jurkat	IC₅₀	8.3 μM Compound: Tamoxifen	Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 23792352]
K562	GI₅₀	5.2 μM Compound: tamoxifen	Antiproliferative activity against human K562 cells after 72 hrs Antiproliferative activity against human K562 cells after 72 hrs	[PMID: 25420175]
MCF-10A	IC₅₀	> 1000 μM Compound: Tamoxifen	Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
MCF-10A	IC₅₀	> 1000 μM Compound: Tamoxifen	Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
MCF-10A	IC₅₀	> 50 μM Compound: Tamoxifen	Cytotoxicity against human MCF-10A cells after 48 hrs by MTT assay Cytotoxicity against human MCF-10A cells after 48 hrs by MTT assay	[PMID: 33340662]
MCF7	IC₅₀	< 1000 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
MCF7	EC₅₀	> 200 nM Compound: 2	Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay	[PMID: 34251202]
MCF7	IC₅₀	0.027 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 22472045]
MCF7	IC₅₀	0.794 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 5 days Cytotoxicity against human MCF7 cells after 5 days	[PMID: 23864928]
MCF7	IC₅₀	1 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 20451380]
MCF7	IC₅₀	1.31 μg/mL Compound: Tamoxifen	Antiproliferative activity against human MCF-7 cells assessed as inhibition of colony formation measured after 3 weeks by crystal violet staining based soft agar colony formation assay Antiproliferative activity against human MCF-7 cells assessed as inhibition of colony formation measured after 3 weeks by crystal violet staining based soft agar colony formation assay	[PMID: 31884407]
MCF7	GI₅₀	1.58 μM Compound: TAM	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
MCF7	IC₅₀	1.82 μM Compound: TAMOX, TAM	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 23123017]
MCF7	IC₅₀	1.89 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24721727]
MCF7	EC₅₀	10 nM Compound: 3 (Tamoxifen)	Effective concentration against MCF-7 breast tumor cells using MCF-7 assay. Effective concentration against MCF-7 breast tumor cells using MCF-7 assay.	[PMID: 12825935]
MCF7	IC₅₀	10 μM Compound: tamoxifene	Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay	[PMID: 19423356]
MCF7	IC₅₀	10.74 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells incubated for 72 hrs by Sulphorhodamine assay Cytotoxicity against human MCF7 cells incubated for 72 hrs by Sulphorhodamine assay	[PMID: 37146520]
MCF7	IC₅₀	10.87 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 31546197]
MCF7	IC₅₀	10.9 μM Compound: Tamoxifen	Cytotoxicity against human adriamycin- resistant MCF7 cells by WST-1 assay Cytotoxicity against human adriamycin- resistant MCF7 cells by WST-1 assay	[PMID: 19836230]
MCF7	IC₅₀	11 μM Compound: Tamoxifen	Inhibitory concentration against MCF-7 (ER+) cell line using SRB assay Inhibitory concentration against MCF-7 (ER+) cell line using SRB assay	[PMID: 12565971]
MCF7	IC₅₀	11.1 μM Compound: Tamoxifen	Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay	[PMID: 19836230]
MCF7	IC₅₀	11.35 μM Compound: Tamoxifen	Antiproliferative activity against ER positive human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against ER positive human MCF7 cells after 48 hrs by MTT assay	[PMID: 28460819]
MCF7	IC₅₀	11.4 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells by WST-1 assay Cytotoxicity against human MCF7 cells by WST-1 assay	[PMID: 19836230]
MCF7	IC₅₀	11.44 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23022281]
MCF7	IC₅₀	11.55 μM Compound: Tamoxifen	Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
MCF7	IC₅₀	11.8 μM Compound: Tamoxifen	Anticancer activity against human MCF7 cells expressing estrogen receptor by MTT assay Anticancer activity against human MCF7 cells expressing estrogen receptor by MTT assay	[PMID: 20951035]
MCF7	IC₅₀	12 μM Compound: tamoxifen	Anticancer activity against estrogen-positive human MCF7 cells after 18 hrs by MTT assay Anticancer activity against estrogen-positive human MCF7 cells after 18 hrs by MTT assay	[PMID: 19446930]
MCF7	GI₅₀	12 μM Compound: 1	Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue assay Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue assay	[PMID: 23735829]
MCF7	IC₅₀	12.35 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23830503]
MCF7	IC₅₀	12.48 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay	[PMID: 21871812]
MCF7	IC₅₀	12.5 μM Compound: Tam	Cytotoxicity against human MCF7 cells expressing ER after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells expressing ER after 48 hrs by MTT assay	10.1039/C4MD00289J
MCF7	IC₅₀	13.45 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23902804]
MCF7	IC₅₀	13.7 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells by MTT reduction assay Antiproliferative activity against human MCF7 cells by MTT reduction assay	[PMID: 33421712]
MCF7	IC₅₀	14.35 μM Compound: Tamoxifen	Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 28942113]
MCF7	IC₅₀	15.2 μM Compound: 6	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23880359]
MCF7	IC₅₀	15.21 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 33340662]
MCF7	IC₅₀	15.46 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29587221]
MCF7	IC₅₀	15.6 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
MCF7	IC₅₀	16.7 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30384047]
MCF7	IC₅₀	18.18 μM Compound: Tamoxifen	Anticancer activity against human ER-positive MCF7 cells measured after 48 hrs by SRB assay Anticancer activity against human ER-positive MCF7 cells measured after 48 hrs by SRB assay	[PMID: 27671497]
MCF7	IC₅₀	18.71 μM Compound: tamoxifen	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay	[PMID: 25734623]
MCF7	IC₅₀	19.2 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin based fluorescence assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin based fluorescence assay	[PMID: 33852304]
MCF7	IC₅₀	19.33 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay	[PMID: 27311894]
MCF7	IC₅₀	19.5 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29482944]
MCF7	IC₅₀	19.54 μM Compound: Tam	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 24 hrs by MTT assay	[PMID: 22647217]
MCF7	IC₅₀	2.1 μM Compound: tamoxifen	Antiproliferative activity against human MCF7 cells after 5 days by WST-8 assay Antiproliferative activity against human MCF7 cells after 5 days by WST-8 assay	[PMID: 25614118]
MCF7	IC₅₀	20 nM Compound: 7	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 33479633]
MCF7	IC₅₀	200 nM Compound: Tamoxifen	Antagonist activity at ERalpha receptor in human MCF7 cells assessed as inhibition of cell growth after 6 days by crystal violet staining method Antagonist activity at ERalpha receptor in human MCF7 cells assessed as inhibition of cell growth after 6 days by crystal violet staining method	[PMID: 23448346]
MCF7	IC₅₀	21.57 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 28505536]
MCF7	IC₅₀	22.6 μM Compound: TAM	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31620225]
MCF7	IC₅₀	25 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay Antiproliferative activity against human MCF7cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay	[PMID: 31673312]
MCF7	IC₅₀	25 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells by fluorescence based viable cell counting method Antiproliferative activity against human MCF7 cells by fluorescence based viable cell counting method	[PMID: 31610378]
MCF7	IC₅₀	27.96 μM Compound: 1, TAM	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 23860592]
MCF7	IC₅₀	3.8 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as cell viability by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability by MTT assay	[PMID: 26079090]
MCF7	IC₅₀	3.99 μg/mL Compound: Tamoxifen	Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay	[PMID: 28442256]
MCF7	IC₅₀	30 nM Compound: Tam	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay	[PMID: 33257172]
MCF7	IC₅₀	31 μM Compound: TEM	Cytotoxicity activity against human MCF7 cells by MTS assay Cytotoxicity activity against human MCF7 cells by MTS assay	[PMID: 21680064]
MCF7	IC₅₀	4 μM Compound: TAM	Cytotoxicity against human MCF7 Cells after 48 hrs by neutral red dye-based assay Cytotoxicity against human MCF7 Cells after 48 hrs by neutral red dye-based assay	[PMID: 31129455]
MCF7	IC₅₀	4.1 μM Compound: 2a	Antiproliferative activity against ER-dependent human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against ER-dependent human MCF7 cells after 72 hrs by MTT assay	[PMID: 28426931]
MCF7	IC₅₀	4.1 μM Compound: 2	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 25369367]
MCF7	IC₅₀	4.1 μM Compound: Tamoxifen	Antiproliferative activity against ER-positive human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by AlamarBlue assay Antiproliferative activity against ER-positive human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by AlamarBlue assay	[PMID: 27407030]
MCF7	IC₅₀	4.12 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 31987694]
MCF7	IC₅₀	4.12 μM Compound: 1a	Antiproliferative activity against estrogen receptor dependent human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against estrogen receptor dependent human MCF7 cells after 72 hrs by MTT assay	[PMID: 18835176]
MCF7	IC₅₀	4.4 μM Compound: TAM	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 26896706]
MCF7	IC₅₀	4.4 μM Compound: 2a	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by SRB assay	[PMID: 28426931]
MCF7	IC₅₀	4.67 μM Compound: Tam	Antiproliferative activity human ER-positive MCF7 cells after 2 days by MTT assay Antiproliferative activity human ER-positive MCF7 cells after 2 days by MTT assay	[PMID: 25222876]
MCF7	IC₅₀	42.4 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 30731397]
MCF7	ED₅₀	5 μg/mL Compound: TAM	Cytotoxicity against human MCF7 cells expressing estrogen receptor after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells expressing estrogen receptor after 72 hrs by SRB assay	[PMID: 19425534]
MCF7	IC₅₀	5.09 μM Compound: TAM	Antiproliferative activity against MCF7 cells at 3 mg/kg/day after 48 hrs Antiproliferative activity against MCF7 cells at 3 mg/kg/day after 48 hrs	[PMID: 16979337]
MCF7	IC₅₀	5.19 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 23806014]
MCF7	IC₅₀	5.3 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 27176944]
MCF7	IC₅₀	5.3 μM Compound: Tamoxifen	Growth inhibition of human MCF7 cells after 72 hrs by MTT assay Growth inhibition of human MCF7 cells after 72 hrs by MTT assay	[PMID: 29220789]
MCF7	IC₅₀	5.4 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 34726897]
MCF7	IC₅₀	5.5 μM Compound: TAM	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23287057]
MCF7	IC₅₀	5.62 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 33894490]
MCF7	IC₅₀	50 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay	[PMID: 36846377]
MCF7	IC₅₀	50 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 36846377]
MCF7	IC₅₀	50 μM Compound: Tamoxifen	Cytotoxicity against human ER-positive MCF7 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human ER-positive MCF7 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26972118]
MCF7	IC₅₀	54 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 33234343]
MCF7	IC₅₀	55.5 μM Compound: Tamoxifen	Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay	10.1007/s00044-012-0391-5
MCF7	IC₅₀	580 nM Compound: tamoxifen	Antiproliferative activity against human MCF7 cells after 24 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTS assay	[PMID: 18272256]
MCF7	IC₅₀	580 nM Compound: 3 (Tamoxifen)	Inhibitory concentration against MCF-7 breast tumor cells using MCF-7 assay. Inhibitory concentration against MCF-7 breast tumor cells using MCF-7 assay.	[PMID: 12825935]
MCF7	IC₅₀	6 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 24880230]
MCF7	IC₅₀	6.3 μM Compound: Tamoxifen	Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay	[PMID: 33373820]
MCF7	GI₅₀	6.5 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by trypan blue assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by trypan blue assay	[PMID: 27128175]
MCF7	GI₅₀	6.8 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 120 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 120 hrs by MTT assay	[PMID: 28152429]
MCF7	IC₅₀	6.99 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells by resazurin microplate assay Cytotoxicity against human MCF7 cells by resazurin microplate assay	[PMID: 27228159]
MCF7	IC₅₀	64.3 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 25164760]
MCF7	IC₅₀	7.09 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 30360952]
MCF7	IC₅₀	7.1 μM Compound: 2	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 22749392]
MCF7	IC₅₀	7.65 μM Compound: TAM	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 19740667]
MCF7	IC₅₀	7.94 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 72 hrs by resazurin based fluorescence assay Cytotoxicity against human MCF7 cells after 72 hrs by resazurin based fluorescence assay	[PMID: 28927795]
MCF7	IC₅₀	8 μg/mL Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 24576797]
MCF7	GI₅₀	8 μM Compound: Tamoxifen	Anti-proliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
MCF7	IC₅₀	8.12 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29054359]
MCF7	IC₅₀	8.31 μg/mL Compound: TAM	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 21115211]
MCF7	IC₅₀	8.38 μg/mL Compound: Tamoxifen	Anticancer activity against human MCF7 cells assessed a cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human MCF7 cells assessed a cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 32771798]
MCF7	IC₅₀	8.42 μM Compound: TAM	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34153643]
MCF7	IC₅₀	8.5 μg/mL Compound: Tamoxifen	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 36325400]
MCF7	IC₅₀	8.53 μM Compound: 1	Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 35276362]
MCF7	IC₅₀	8.6 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 72 hrs by WST1 assay in presence of 20% FBS Cytotoxicity against human MCF7 cells after 72 hrs by WST1 assay in presence of 20% FBS	[PMID: 22901895]
MCF7	IC₅₀	8.61 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
MCF7	IC₅₀	8.9 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 20605470]
MCF7	IC₅₀	82.5 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25164760]
MCF7	IC₅₀	9 μM Compound: Tamoxifen	Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 32731188]
MCF7	IC₅₀	9 μM Compound: TAM	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 24457094]
MCF7	IC₅₀	9.6 μM Compound: Tamoxifen	Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33373820]
MDA-MB-231	IC₅₀	< 1000 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
MDA-MB-231	IC₅₀	> 20 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
MDA-MB-231	IC₅₀	> 50 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay	[PMID: 34022716]
MDA-MB-231	IC₅₀	> 50 μM Compound: Tamoxifen	Cytotoxicity against human ER-negative MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human ER-negative MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26972118]
MDA-MB-231	IC₅₀	0.66 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	[PMID: 20451380]
MDA-MB-231	IC₅₀	10 μM Compound: TAM	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 24457094]
MDA-MB-231	IC₅₀	10 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 20605470]
MDA-MB-231	IC₅₀	10.11 μM Compound: TAM	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34153643]
MDA-MB-231	IC₅₀	11.2 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	[PMID: 31546197]
MDA-MB-231	IC₅₀	11.4 μM Compound: TAM	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 23287057]
MDA-MB-231	IC₅₀	12.4 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells by WST-1 assay Cytotoxicity against human MDA-MB-231 cells by WST-1 assay	[PMID: 19836230]
MDA-MB-231	IC₅₀	12.41 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 23022281]
MDA-MB-231	IC₅₀	13.9 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay	[PMID: 27176944]
MDA-MB-231	IC₅₀	14 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 24880230]
MDA-MB-231	IC₅₀	14.5 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells by MTT reduction assay Antiproliferative activity against human MDA-MB-231 cells by MTT reduction assay	[PMID: 33421712]
MDA-MB-231	IC₅₀	14.94 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 35276362]
MDA-MB-231	IC₅₀	15.01 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 33894490]
MDA-MB-231	GI₅₀	15.1 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 120 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 120 hrs by MTT assay	[PMID: 28152429]
MDA-MB-231	IC₅₀	17 μM Compound: Tamoxifen	Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
MDA-MB-231	IC₅₀	18.48 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Sulphorhodamine assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Sulphorhodamine assay	[PMID: 37146520]
MDA-MB-231	IC₅₀	18.9 μM Compound: Tamoxifen	Antiproliferative activity against estrogen receptor-deficient human MDA-MB-231 cells expressing estrogen receptor after 48 hrs by MTT assay Antiproliferative activity against estrogen receptor-deficient human MDA-MB-231 cells expressing estrogen receptor after 48 hrs by MTT assay	[PMID: 21871812]
MDA-MB-231	IC₅₀	19 μM Compound: Tamoxifen	Inhibitory concentration against MDA-MB-231 (ER-) cell line using SRB assay Inhibitory concentration against MDA-MB-231 (ER-) cell line using SRB assay	[PMID: 12565971]
MDA-MB-231	IC₅₀	20 μM Compound: tamoxifene	Antiproliferative activity against human estrogen receptor deficient MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human estrogen receptor deficient MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 19423356]
MDA-MB-231	IC₅₀	24 μM Compound: tamoxifen	Anticancer activity against estrogen-positive human MDA-MB-231 cells after 18 hrs by MTT assay Anticancer activity against estrogen-positive human MDA-MB-231 cells after 18 hrs by MTT assay	[PMID: 19446930]
MDA-MB-231	IC₅₀	25.1 μM Compound: Tamoxifen	Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay	10.1007/s00044-012-0391-5
MDA-MB-231	IC₅₀	27 μM Compound: Tam	Cytotoxicity against human ER negative MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human ER negative MDA-MB-231 cells after 48 hrs by MTT assay	10.1039/C4MD00289J
MDA-MB-231	IC₅₀	35.8 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 33340662]
MDA-MB-231	IC₅₀	38.97 μM Compound: Tam	Antiproliferative activity human ER-negative MDA-MB-231 cells after 2 days by MTT assay Antiproliferative activity human ER-negative MDA-MB-231 cells after 2 days by MTT assay	[PMID: 25222876]
MDA-MB-231	IC₅₀	47.1 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 30360952]
MDA-MB-231	IC₅₀	5.9 μM Compound: Tamoxifen	Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay	[PMID: 33373820]
MDA-MB-231	IC₅₀	64.85 μM Compound: 1, TAM	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 23860592]
MDA-MB-231	IC₅₀	69.7 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-231	IC₅₀	7 μM Compound: Tamoxifen	Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33373820]
MDA-MB-231	IC₅₀	7.85 μg/mL Compound: Tamoxifen	Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay	[PMID: 28442256]
MDA-MB-231	IC₅₀	75 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 33234343]
MDA-MB-231	IC₅₀	75 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 25164760]
MDA-MB-231	IC₅₀	84.6 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25164760]
MDA-MB-231	IC₅₀	9.86 μM Compound: TAM	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 19740667]
MDA-MB-231	IC₅₀	9.96 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29054359]
MDA-MB-435	GI₅₀	3.16 μM Compound: TAM	Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
MDA-MB-435S	IC₅₀	5.5 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-435S cells assessed as cell viability by MTT assay Cytotoxicity against human MDA-MB-435S cells assessed as cell viability by MTT assay	[PMID: 26079090]
MDA-MB-468	IC₅₀	14.99 μM Compound: Tam	Cytotoxicity against human ER negative MDA-MB-468 cells after 48 hrs by MTT assay Cytotoxicity against human ER negative MDA-MB-468 cells after 48 hrs by MTT assay	10.1039/C4MD00289J
MDA-MB-468	GI₅₀	2.5 μM Compound: TAM	Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
MEL-JUSO	EC₅₀	14.6 μM Compound: TAM	Antiproliferative activity against human MelJuSo cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay Antiproliferative activity against human MelJuSo cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay	[PMID: 31099568]
M-HeLa	IC₅₀	28 μM Compound: Tamoxifen	Antiproliferative activity against human M-HeLa cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay Antiproliferative activity against human M-HeLa cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay	[PMID: 31673312]
M-HeLa	IC₅₀	28 μM Compound: Tamoxifen	Antiproliferative activity against human M-HeLa cells by fluorescence based viable cell counting method Antiproliferative activity against human M-HeLa cells by fluorescence based viable cell counting method	[PMID: 31610378]
MIA PaCa-2	IC₅₀	33.12 μM Compound: Tam	Antiproliferative activity human MIAPaCa2 cells after 2 days by MTT assay Antiproliferative activity human MIAPaCa2 cells after 2 days by MTT assay	[PMID: 25222876]
MOLT-4	GI₅₀	2.5 μM Compound: TAM	Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
MRC5	CC₅₀	10 μM Compound: Tamoxifen	Cytotoxicity against human MRC5 cells measured after 7 days by MTT assay Cytotoxicity against human MRC5 cells measured after 7 days by MTT assay	[PMID: 33667089]
MRC5	IC₅₀	10.9 μM Compound: TAM	Cytotoxicity against human MRC5 cells assessed as cell viability after 4 to 7 days by Alamar Blue staining based fluorometric analysis Cytotoxicity against human MRC5 cells assessed as cell viability after 4 to 7 days by Alamar Blue staining based fluorometric analysis	[PMID: 26922226]
MRC5	IC₅₀	11.09 μM Compound: Tamoxifen	Cytotoxicity in human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-based cytotoxicity assay Cytotoxicity in human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-based cytotoxicity assay	[PMID: 30879839]
MRC5	CC₅₀	11.09 μM Compound: Tamoxifen	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by resazurin dye based fluorimetric assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by resazurin dye based fluorimetric assay	[PMID: 30857749]
MRC5	IC₅₀	11.09 μM Compound: Tamoxifen	Cytotoxicity against human MRC5 cells after 24 hrs by resazurin dye based assay Cytotoxicity against human MRC5 cells after 24 hrs by resazurin dye based assay	[PMID: 30692024]
MRC5	IC₅₀	17.2 μM Compound: Tamoxifen	Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis	[PMID: 36242986]
MSTO-211H	GI₅₀	23.3 μM Compound: 1	Antiproliferative activity against human MSTO-211H cells after 72 hrs by trypan blue assay Antiproliferative activity against human MSTO-211H cells after 72 hrs by trypan blue assay	[PMID: 23735829]
NCI/ADR-RES	IC₅₀	11.13 μM Compound: Tamoxifen	Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay	[PMID: 23022281]
NCI-H460	GI₅₀	4.48 μM Compound: Tamoxifen	Anticancer activity against human NCI-H460 cells after 24 hrs by SRB assay Anticancer activity against human NCI-H460 cells after 24 hrs by SRB assay	[PMID: 19733085]
NIH3T3	IC₅₀	> 100 μM Compound: Tam	Antiproliferative activity mouse NIH/3T3 cells after 2 days by MTT assay Antiproliferative activity mouse NIH/3T3 cells after 2 days by MTT assay	[PMID: 25222876]
NIH3T3	IC₅₀	11.4 μM Compound: TAM	Antiproliferative activity against mouse NIH/3T3 cells after 48 hrs by MTT assay Antiproliferative activity against mouse NIH/3T3 cells after 48 hrs by MTT assay	[PMID: 23287057]
NIH3T3	IC₅₀	7.26 μM Compound: 2	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 22749392]
OVCAR-5	GI₅₀	32 μM Compound: 1	Cytotoxicity against human OVCAR5 cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against human OVCAR5 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 27128175]
PC-3	IC₅₀	> 1000 nM Compound: 7	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 33479633]
PC-3	IC₅₀	10 μM Compound: TAM	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 23287057]
PC-3	IC₅₀	15.8 μM Compound: TAM	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34153643]
PC-3	IC₅₀	7 μM Compound: Tamoxifen	Antiproliferative activity against human PC3 cells after 24 hrs by MTT assay Antiproliferative activity against human PC3 cells after 24 hrs by MTT assay	[PMID: 24880230]
RAW264.7	CC₅₀	11.1 μM Compound: Tamoxifen	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by neutral red dye based assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by neutral red dye based assay	[PMID: 31703818]
RAW264.7	IC₅₀	18.5 μM Compound: Tamoxifen	Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis	[PMID: 36242986]
SH-SY5Y	IC₅₀	20 μM Compound: Tamoxifen	Inhibition of PKC in human SH-SY5Y cells assessed as inhibition of PMA-stimulated MARCKS phosphorylation preincubated for 1 hr followed by PMA-stimulation for 15 mins by Western blot analysis Inhibition of PKC in human SH-SY5Y cells assessed as inhibition of PMA-stimulated MARCKS phosphorylation preincubated for 1 hr followed by PMA-stimulation for 15 mins by Western blot analysis	[PMID: 27647375]
SK-BR-3	IC₅₀	< 1000 μM Compound: Tamoxifen	Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
SK-BR-3	GI₅₀	12.5 μM Compound: Tamoxifen	Cytotoxicity against human SKBR3 cells assessed as growth inhibition after 120 hrs by MTT assay Cytotoxicity against human SKBR3 cells assessed as growth inhibition after 120 hrs by MTT assay	[PMID: 28152429]
SK-BR-3	IC₅₀	28.32 μM Compound: Tamoxifen	Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay	[PMID: 33340662]
SK-BR-3	ED₅₀	5 μg/mL Compound: TAM	Cytotoxicity against estrogen receptor deficient human SKBR3 cells overexpressing human epidermal growth factor receptor 2 after 72 hrs by SRB assay Cytotoxicity against estrogen receptor deficient human SKBR3 cells overexpressing human epidermal growth factor receptor 2 after 72 hrs by SRB assay	[PMID: 19425534]
SK-MEL-28	IC₅₀	1.86 μg/mL Compound: Tomoxifen	Cytotoxicity against human SK-MEL-28 cells by alamar blue assay Cytotoxicity against human SK-MEL-28 cells by alamar blue assay	[PMID: 11720540]
SK-OV-3	GI₅₀	10 μM Compound: TAM	Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
SK-OV-3	GI₅₀	6.4 μM Compound: Tamoxifen	Anticancer activity against human SKOV3 cells after 24 hrs by SRB assay Anticancer activity against human SKOV3 cells after 24 hrs by SRB assay	[PMID: 19733085]
SNB-75	GI₅₀	5.01 μM Compound: TAM	Cytotoxicity against human SNB75 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human SNB75 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
T47D	IC₅₀	0.1 μM Compound: Tamoxifen	Antiestrogenic activity in human T47D cells expressing estrogen receptor assessed as estrogen-dependent transcription by luciferase reporter gene assay Antiestrogenic activity in human T47D cells expressing estrogen receptor assessed as estrogen-dependent transcription by luciferase reporter gene assay	[PMID: 19131248]
T47D	IC₅₀	1 μM Compound: Tamoxifen	Growth inhibition of human estrogen-dependent T47D cells after 72 hrs Growth inhibition of human estrogen-dependent T47D cells after 72 hrs	[PMID: 19131248]
T47D	IC₅₀	1.13 μM Compound: Tamoxifen	Cytotoxicity against human T47D cells after 5 days Cytotoxicity against human T47D cells after 5 days	[PMID: 23864928]
T47D	GI₅₀	1.99 μM Compound: TAM	Cytotoxicity against human T47D cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human T47D cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
T47D	GI₅₀	10.6 μM Compound: Tamoxifen	Cytotoxicity against human T47D cells assessed as growth inhibition after 120 hrs by MTT assay Cytotoxicity against human T47D cells assessed as growth inhibition after 120 hrs by MTT assay	[PMID: 28152429]
T47D	IC₅₀	12.1 μM Compound: Tamoxifen	Cytotoxicity against Homo sapiens (human) T47D cells assessed as inhibition of cell proliferation after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) T47D cells assessed as inhibition of cell proliferation after 72 hr by MTT assay	10.1007/s00044-012-0391-5
T47D	IC₅₀	13 μM Compound: TAM	Antiproliferative activity against human T47D cells after 48 hrs by MTT assay Antiproliferative activity against human T47D cells after 48 hrs by MTT assay	[PMID: 23287057]
T47D	IC₅₀	14.2 μM Compound: Tamoxifen	Antiproliferative activity against human T47D cells by MTT reduction assay Antiproliferative activity against human T47D cells by MTT reduction assay	[PMID: 33421712]
T47D	IC₅₀	29.9 μM Compound: Tam	Cytotoxicity against human T47D cells expressing ER after 48 hrs by MTT assay Cytotoxicity against human T47D cells expressing ER after 48 hrs by MTT assay	10.1039/C4MD00289J
T47D	IC₅₀	34.42 μM Compound: Tamoxifen	Antiproliferative activity against human T47D cells after 24 hrs by MTT assay Antiproliferative activity against human T47D cells after 24 hrs by MTT assay	[PMID: 30731397]
THP-1	IC₅₀	11.91 μM Compound: Tamoxifen	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
UO-31	GI₅₀	6.3 μM Compound: TAM	Cytotoxicity against human UO31 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human UO31 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
Vero	IC₅₀	15.9 μM Compound: Tamoxifen	Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
Vero	IC₅₀	36.2 μM Compound: Tamoxifen	Cytotoxicity against african green monkey Vero cells incubated for 72 hrs by Sulphorhodamine assay Cytotoxicity against african green monkey Vero cells incubated for 72 hrs by Sulphorhodamine assay	[PMID: 37146520]
Vero	IC₅₀	5.7 μM Compound: Tamoxifen	Cytotoxicity against African green monkey Vero cells assessed as cell viability by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell viability by MTT assay	[PMID: 26079090]

In Vitro

Tamoxifen (ICI 47699) shows strong inhibition of MCF-7 cells (EC₅₀=1.41 μM) and to a lesser extent the T47D cells (EC₅₀=2.5 μM) but does not affect the MDA-MB-231 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tamoxifen-inducible gene knockout strategy has clear advantages in that expression of a gene can be ablated in adult mice at will in a tissue specific manner. To study the role of Med1 in adult heart, 7-week old TmcsMed1^-/- mice are given a daily Iintraperitoneal injection of Tamoxifen at a dose of 65 mg/kg (Tamoxifen Citrate) for 5 days and killed at selected intervals thereafter. qPCR analysis of RNA shows that the Med1 expression begin to decrease after 3 days of Tamoxifen injection (about 70% decrease), and by 5 days of injection, Med1 expression is almost non-detectable in the heart. Tamoxifen-inducible cardiac-specific disruption of Med1 (TmcsMed1^-/-) in adult mice causes dilated cardiomyopathy^[3].

1. Induction of gene knockout^[8]^[9]

Background

Gene knockout model induced by tamoxifen uses Cre-Loxp mice. The Cre recombinase in these mice is driven by a tissue/cell-specific promoter, and the target gene is flanked by Loxp sites. The Cre recombinase is fused with the ligand-binding domain of the estrogen receptor to construct a Cre-ER fusion protein, and the recombination activity of Cre is induced by tamoxifen. In the absence of tamoxifen, the Cre-ER fusion protein binds to HSP90 and remains in the cytoplasm. After tamoxifen induction, the metabolite of tamoxifen, 4-OHT, binds to the Cre-ER protein, activates the Cre recombinase, and allows it to enter the nucleus. There, it recognizes the Loxp sites and mediates the knockout of the gene between two (in the same orientation) Loxp sites. (To avoid interference from endogenous estrogens, the ligand-binding domain of the estrogen receptor is modified, transforming Cre-ER into MerCreMer, Cre-ERT, or Cre-ERT2).

Specific Modeling Methods

Mice: Cx3cr1^CreERT/+: Pdgfb^fl/fl (Conditional knockout of Pdgfb in microglia)
Administration: i.p. • 5 consecutive days

Note

(1) Dissolution: Tamoxifen is poorly soluble in water and is generally dissolved in corn oil. It can be heated at 37°C or sonicated to assist dissolution, ensuring complete dissolution. Tamoxifen should be prepared in the dark and is recommended to be used freshly prepared. Corn oil is relatively viscous. When aspirating the solution, the needle can be left unplugged. After aspirating the solution, attach the needle and expel the air bubbles.
(2) Administration methods: Common methods include intraperitoneal injection, and it can also be administered by oral gavage or subcutaneous injection. When performing multiple intraperitoneal injections, the injection sites should be alternated.
(3) Dosage: The dosage is 50-120 mg/kg, with 3-5 intraperitoneal injections, usually for 5 consecutive days. The dosage for pregnant mice and aged mice (over 6 months old) should be appropriately reduced. Tamoxifen can affect fetal development and parturition. For pregnant mice, the induction time should preferably be selected in the late pregnancy stage, and progesterone should be injected simultaneously to reduce the probability of miscarriage.
(4) Mice: Mice at 4-6 weeks old may be more sensitive (it is more effective in young mice than in old mice).
(5) Potential toxicity: Prolonged high-level Cre activity can cause potential toxicity. In addition, if an important functional gene is knocked out, it may also lead to the death of mice. Therefore, close observation should be carried out within one or two weeks after induction. If the mice show abnormalities, the causes need to be analyzed in a timely manner and the experimental plan should be adjusted.
(6) Control: Control group mice should be injected with an equal amount of the corn oil solution of tamoxifen (using tamoxifen in a genetic background without Cre recombinase) to rule out the influence of tamoxifen itself.
(7) Detection window: The time window between tamoxifen administration and the start of the experiment should be large enough, at least 7 days, to ensure that the Cre recombinase enters the nucleus and functions.
(8) Separate caging: Animals treated with tamoxifen should be caged separately from untreated animals to avoid cross - contamination caused by behaviors such as animals licking the oily tamoxifen suspension, grooming their fur, or coprophagy.

Modeling Indicators

Verify the reduced expression/knockout of the target gene at the RNA or protein level through molecular biology and genetic methods (such as Western blot, PCR, and sequencing, etc.).

Correlated Product(s): 4-Hydroxytamoxifen (HY-16950)

Opposite Product(s): /

2. Induction of liver injury^[10]^[11]

Background

Tamoxifen reduces the hexose monophosphate shunt, thereby increasing the incidence of oxidative stress in rat hepatocytes, leading to liver injury.

Specific Modeling Methods

Albino rat &bull ; female &bull ; period: 7 days
Administration: 45 mg/kg •ip • once daily for 7 days

Note

(1) The rats were kept in a standard laboratory environment, which was a 12-hour light/12-hour dark cycle with the temperature maintained at 25 ± 2°C. They had free access to food and water.
(2) At the end of the experiment, the animals were euthanized by cervical dislocation under mild ether anesthesia. The blood samples were collected in heparinized centrifuge tubes and centrifuged to obtain serum. The abdomen was opened, and the liver was immediately dissected and removed. It was washed with ice-cold isotonic saline and blotted between two filter papers. The liver was wrapped in aluminum foil and stored at -80°C. A 10% (w/v) liver homogenate was prepared in ice-cold 0.1 M potassium phosphate buffer (pH 7.5) using an ultrasonicator.

Modeling Indicators

Molecular Changes: The activities of antioxidant enzymes, including glutathione S-transferase, glutathione peroxidase, and catalase, were significantly ↓, while the content of reduced glutathione also showed a ↓ trend. Concurrently, the levels of thiobarbituric acid reactive substances (TBARS) and liver transaminases, including serum glutamic-pyruvic transaminase (sGPT) and serum glutamic-oxaloacetic transaminase (sGOT), were significantly ↑.

Correlated Product(s): /

Opposite Product(s): /

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Aldh1l1-cre/ERT2 x Ai95 mice^[3]
Dosage:	75 mg/kg
Administration:	Injected for 5 days at 6 weeks of age
Result:	Resulted in the excision of the floxed exon and a gene knockout.

Clinical Trial

Molecular Weight

371.51

Formula

C₂₆H₂₉NO

CAS No.

10540-29-1

Appearance

Solid

Color

White to off-white

SMILES

CC/C(C1=CC=CC=C1)=C(C2=CC=CC=C2)/C3=CC=C(C=C3)OCCN(C)C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

Ethanol : 50 mg/mL (134.59 mM; Need ultrasonic)

DMSO : 25 mg/mL (67.29 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6917 mL	13.4586 mL	26.9172 mL
5 mM	0.5383 mL	2.6917 mL	5.3834 mL
10 mM	0.2692 mL	1.3459 mL	2.6917 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (5.60 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Corn Oil
Solubility: 40 mg/mL (107.67 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.92%

Select Batch:

Data Sheet (292 KB) SDS (761 KB)

COA (248 KB) LCMS (112 KB) Elemental Analysis Report (106 KB)

Handling Instructions (2659 KB)

References

[1]. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26;339(22):1609-18. [Content Brief]

[2]. Hawariah A, et al. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity. Anticancer Res. 1998 Nov-Dec;18(6A):4383-6. [Content Brief]

[3]. Jun Nagai, et al. Hyperactivity with Disrupted Attention by Activation of an Astrocyte Synaptogenic Cue. Cell. 2019 May 16;177(5):1280-1292.e20. [Content Brief]

[4]. Zhao R, et al. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. PLoS One. 2010 Apr 1;5(4):e9934. [Content Brief]

[5]. Kedjouar B, et al. Molecular characterization of the microsomal tamoxifen binding site. J Biol Chem. 2004 Aug 6;279(32):34048-61. [Content Brief]

[6]. Feil S, et, al. Inducible Cre mice. Methods Mol Biol. 2009;530:343-63. [Content Brief]

[7]. Laura Cooper, et al. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Sep 4. [Content Brief]

[8]. Bi Q, et al. Microglia-derived PDGFB promotes neuronal potassium currents to suppress basal sympathetic tonicity and limit hypertension. Immunity. 2022 Aug 9;55(8):1466-1482.e9. [Content Brief]

[9]. Chen MY, et al. A review of tamoxifen administration regimen optimization for Cre/loxp system in mouse bone study. Biomed Pharmacother. 2023 Sep;165:115045. [Content Brief]

[10]. El-Beshbishy HA. Hepatoprotective effect of green tea (Camellia sinensis) extract against tamoxifen-induced liver injury in rats. J Biochem Mol Biol. 2005 Sep 30;38(5):563-70. [Content Brief]

[11]. El-Beshbishy H A. The effect of dimethyl dimethoxy biphenyl dicarboxylate (DDB) against tamoxifen-induced liver injury in rats: DDB use is curative or protective[J]. BMB Reports, 2005, 38(3): 300-306. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / Ethanol	1 mM	2.6917 mL	13.4586 mL	26.9172 mL	67.2929 mL
	5 mM	0.5383 mL	2.6917 mL	5.3834 mL	13.4586 mL
	10 mM	0.2692 mL	1.3459 mL	2.6917 mL	6.7293 mL
	15 mM	0.1794 mL	0.8972 mL	1.7945 mL	4.4862 mL
	20 mM	0.1346 mL	0.6729 mL	1.3459 mL	3.3646 mL
	25 mM	0.1077 mL	0.5383 mL	1.0767 mL	2.6917 mL
	30 mM	0.0897 mL	0.4486 mL	0.8972 mL	2.2431 mL
	40 mM	0.0673 mL	0.3365 mL	0.6729 mL	1.6823 mL
	50 mM	0.0538 mL	0.2692 mL	0.5383 mL	1.3459 mL
	60 mM	0.0449 mL	0.2243 mL	0.4486 mL	1.1215 mL
Ethanol	80 mM	0.0336 mL	0.1682 mL	0.3365 mL	0.8412 mL
Ethanol	100 mM	0.0269 mL	0.1346 mL	0.2692 mL	0.6729 mL

Tamoxifen Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Tamoxifen (Synonyms: ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen)

Customer Review

Other Forms of Tamoxifen:

139 Publications Citing Use of MCE Tamoxifen

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Estrogen Receptor/ERR Isoform Specific Products:

View All HSP Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Tamoxifen Related Classifications

Keywords:

Your Recently Viewed Products:

Tamoxifen (Synonyms: ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen)

Customer Review

Other Forms of Tamoxifen:

Tamoxifen Related Antibodies

139 Publications Citing Use of MCE Tamoxifen

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Estrogen Receptor/ERR Isoform Specific Products:

View All HSP Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Tamoxifen Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Tamoxifen Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report